Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06226571 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06226571 · ClinicalTrials.gov record · last posted 2026-06-30

A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

Name: A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias — clinical trial record (NCT06226571)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 1

SponsorSyndax Pharmaceuticals

Started2024-05-21

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of SNDX-5613 in combination with intensive chemotherapy in participants with newly diagnosed acute myeloid leukemia (AML) harboring alterations in KMT2A, NPM1, or NUP98 genes.

Protocol amendment history 1 change detected by DataLookout

2026-07-01

Trial status changed: Recruiting → Active, Not Recruiting

Trial Details

NCT Number	NCT06226571
Lead Sponsor	Syndax Pharmaceuticals
Conditions	Acute Myeloid Leukemias
Enrollment	76 participants
Start Date	2024-05-21
Primary Completion	2027-02 (estimated)
Study Completion	2027-02 (estimated)
Updated on ClinicalTrials.gov	2026-06-30